Silva Krause
Overview
Explore the profile of Silva Krause including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OReilly E, Barone D, Mahalingam D, Bekaii-Saab T, Shao S, Wolf J, et al.
Eur J Cancer
. 2020 May;
132:112-121.
PMID: 32361265
Background: Necuparanib, a rationally engineered low-molecular-weight heparin, combined with gemcitabine/nab-paclitaxel showed an encouraging safety and oncologic signal in a phase Ib trial. This randomised multicentre phase II trial evaluates the...
2.
MacDonald A, Priess M, Curran J, Guess J, Farutin V, Oosterom I, et al.
Mol Cancer Ther
. 2018 Nov;
18(2):245-256.
PMID: 30401693
Pancreatic cancer has an abysmal 5-year survival rate of 8%, making it a deadly disease with a need for novel therapies. Here we describe a multitargeting heparin-based mimetic, necuparanib, and...
3.
OReilly E, Roach J, Miller P, Yu K, Tjan C, Rosano M, et al.
Oncologist
. 2017 Nov;
22(12):1429-e139.
PMID: 29158367
Lessons Learned: Despite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing.Safety was documented,...
4.
Brock A, Krause S, Ingber D
Nat Rev Cancer
. 2015 Jul;
15(8):499-509.
PMID: 26156637
Differentiation therapies that induce malignant cells to stop growing and revert to normal tissue-specific differentiated cell types are successful in the treatment of a few specific haematological tumours. However, this...
5.
Brock A, Krause S, Li H, Kowalski M, Goldberg M, Collins J, et al.
Sci Transl Med
. 2014 Jan;
6(217):217ra2.
PMID: 24382894
With advances in screening, the incidence of detection of premalignant breast lesions has increased in recent decades; however, treatment options remain limited to surveillance or surgical removal by lumpectomy or...
6.
Krause S, Brock A, Ingber D
J Vis Exp
. 2013 Oct;
(80).
PMID: 24121742
Herein we describe a protocol to deliver various reagents to the mouse mammary gland via intraductal injections. Localized drug delivery and knock-down of genes within the mammary epithelium has been...
7.
Werfel J, Krause S, Bischof A, Mannix R, Tobin H, Bar-Yam Y, et al.
PLoS One
. 2013 Oct;
8(10):e76122.
PMID: 24098430
Changes in extracellular matrix (ECM) structure or mechanics can actively drive cancer progression; however, the underlying mechanism remains unknown. Here we explore whether this process could be mediated by changes...
8.
Bischof A, Yuksel D, Mammoto T, Mammoto A, Krause S, Ingber D
Integr Biol (Camb)
. 2013 Jul;
5(8):1045-56.
PMID: 23817524
Some epithelial cancers can be induced to revert to quiescent differentiated tissue when combined with embryonic mesenchyme; however, the mechanism of this induction is unknown. Here we combine tissue engineering,...
9.
Kang J, Krause S, Tobin H, Mammoto A, Kanapathipillai M, Ingber D
Lab Chip
. 2012 Mar;
12(12):2175-81.
PMID: 22453808
Here we describe a combined microfluidic-micromagnetic cell separation device that has been developed to isolate, detect and culture circulating tumor cells (CTCs) from whole blood, and demonstrate its utility using...
10.
Krause S, Jondeau-Cabaton A, Dhimolea E, Soto A, Sonnenschein C, Maffini M
Tissue Eng Part A
. 2011 Sep;
18(5-6):520-32.
PMID: 21919795
Epithelial-mesenchymal interactions during embryogenesis are critical in defining the phenotype of tissues and organs. The initial elongation of the mammary bud represents a central morphological event requiring extensive epithelial-mesenchymal crosstalk....